The FDA on June 22, 2022, granted accelerated approval to TAFINLARĀ® (Dabrafenib) in combination with MEKINISTĀ® (Trametinib) for the treatment of adult and pediatric patients 6 years of age or older with unresectable or metastatic solid tumors with BRAF V600E mutation, who have progressed following prior treatment, and have no satisfactory alternative treatment options. TAFINLARĀ® and MEKINISTĀ® are products of Novartis Pharmaceuticals Corporation.
